Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Turkish Validation of the 9-Item Tampa Scale of Kinesiophobia

23 giugno 2026 aggiornato da: Hatice Gül, Akdeniz University

Turkish Validity and Reliability Study of the 9-Item Tampa Scale of Kinesiophobia in Individuals With Chronic Spinal Pain

This observational methodological study aims to evaluate the validity and reliability of the Turkish version of the 9-item Tampa Scale of Kinesiophobia (TSK-9) in individuals with chronic spinal pain. Chronic spinal pain is commonly associated with fear of movement, avoidance behavior, pain catastrophizing, and disability. Therefore, a short and practical Turkish measurement tool may be useful for both clinical assessment and research.

Participants with chronic neck or low back pain will complete self-report questionnaires, including the Turkish TSK-9, the Fear-Avoidance Beliefs Questionnaire, the Pain Catastrophizing Scale, the Fear-Avoidance Components Scale, and the Numeric Pain Rating Scale. The Turkish TSK-9 will be administered again 7 days after the first assessment in a subgroup of participants to evaluate test-retest reliability.

No intervention, invasive procedure, clinical test, or laboratory test will be performed. Data will be collected online using Google Forms.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study is an observational methodological validation study designed to investigate the psychometric properties of the Turkish version of the 9-item Tampa Scale of Kinesiophobia (TSK-9) in individuals with chronic spinal pain.

The original Tampa Scale of Kinesiophobia is a widely used measure for evaluating fear of movement and reinjury in people with pain. However, shorter versions of the scale have been proposed in the literature, and the 9-item version includes two domains: activity avoidance and somatic focus. The purpose of this study is to translate, culturally adapt, and evaluate the validity and reliability of the Turkish TSK-9 in individuals with chronic neck or low back pain.

The study will be conducted online. Participants will be recruited through social media announcements and will complete the study questionnaires using Google Forms. Eligible participants will be adults aged 18 to 50 years who report chronic spinal pain lasting longer than 3 months and a self-reported pain intensity of at least 3 points on the Numeric Pain Rating Scale.

The first assessment will include sociodemographic and clinical questions, the Turkish TSK-9, the Fear-Avoidance Beliefs Questionnaire, the Pain Catastrophizing Scale, the Fear-Avoidance Components Scale, and the Numeric Pain Rating Scale. Pain intensity will be assessed both at rest and during activity. To evaluate test-retest reliability, the Turkish TSK-9 will be administered again 7 days after the first assessment in participants who agree to complete the second evaluation.

The study will include at least 90 participants. This sample size was determined according to the commonly used participant-to-item ratio of 10 participants per item for questionnaire validation studies. Since the TSK-9 includes 9 items, a minimum of 90 participants is planned.

Reliability will be examined using internal consistency and test-retest reliability analyses. Internal consistency will be assessed using Cronbach's alpha. Test-retest reliability will be evaluated using the intraclass correlation coefficient, 95% confidence interval, standard error of measurement, and minimal detectable change. Construct validity will be examined by analyzing the correlations between the Turkish TSK-9 and measures of fear-avoidance beliefs, pain catastrophizing, fear-avoidance components, and pain intensity.

No treatment, intervention, invasive procedure, clinical test, or laboratory test will be applied in this study. Participation is voluntary, and the study is not expected to involve any physical risk or harm to participants.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

90

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Turchia (Türkiye)
    • Konyaaltı
      • Antalya, Konyaaltı, Turchia (Türkiye), 07070
        • Akdeniz University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population will consist of adults aged 18 to 65 years with chronic spinal pain, including chronic neck or low back pain lasting longer than 3 months. Participants will be recruited online through social media announcements and will complete the study questionnaires using Google Forms. Eligible participants will be individuals who report a pain intensity score of 3 or higher on the Numeric Pain Rating Scale and who are able to read and understand Turkish.

Descrizione

Inclusion Criteria:

  • Being between 18 and 65 years of age
  • Having chronic spinal pain lasting longer than 3 months
  • Having neck or low back pain
  • Having a self-reported pain intensity score of 3 or higher on the Numeric Pain Rating Scale
  • Volunteering to participate in the study
  • Being able to read and understand Turkish

Exclusion Criteria:

  • History of spinal surgery
  • History of vertebral fracture
  • Diagnosis of radiculopathy and/or disc herniation with neurological involvement
  • Use of analgesic medication within the last 7 days
  • History of cancer
  • Self-reported serious neurological disease
  • Self-reported serious psychiatric disease

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Patient with chronic spinal pain
Altro: Questionnaire-based assessment
Participants will complete self-report questionnaires, including the Turkish 9-item Tampa Scale of Kinesiophobia, Fear-Avoidance Beliefs Questionnaire, Pain Catastrophizing Scale, Fear-Avoidance Components Scale, and Numeric Pain Rating Scale. The Turkish 9-item Tampa Scale of Kinesiophobia will be administered again 7 days after the first assessment in a subgroup of participants to evaluate test-retest reliability. No treatment, invasive procedure, clinical test, or laboratory test will be performed.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Turkish version 9-item Tampa Scale of Kinesiophobia
Lasso di tempo: Baseline and 7 days
The Turkish 9-item Tampa Scale of Kinesiophobia (TSK-9) is a self-report questionnaire used to assess fear of movement and reinjury in individuals with pain. The scale consists of 9 items and two domains: activity avoidance and somatic focus. Each item is scored on a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree). The activity avoidance domain includes 5 items and ranges from 5 to 20 points. The somatic focus domain includes 4 items and ranges from 4 to 16 points. Higher scores indicate greater kinesiophobia.
Baseline and 7 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fear-Avoidance Beliefs Questionnaire
Lasso di tempo: Baseline
The Fear-Avoidance Beliefs Questionnaire is a self-report questionnaire used to assess fear-avoidance beliefs related to physical activity and work. It includes 16 items and two subscales: a physical activity subscale and a work subscale. Each item is scored on a 7-point Likert scale ranging from 0 (completely disagree) to 6 (completely agree). Higher scores indicate greater fear-avoidance beliefs.
Baseline
Pain Catastrophizing Scale
Lasso di tempo: Baseline
The Pain Catastrophizing Scale is a self-report questionnaire used to assess catastrophic thoughts and feelings related to pain. It consists of 13 items and includes three subscales. Each item is scored on a 5-point scale. The total score ranges from 0 to 52, with higher scores indicating greater pain catastrophizing.
Baseline
Fear-Avoidance Components Scale
Lasso di tempo: Baseline
The Fear-Avoidance Components Scale is a self-report questionnaire used to assess cognitive, behavioral, and emotional components of fear avoidance in individuals with painful medical conditions. It consists of 20 items scored from 0 (completely disagree) to 5 (completely agree). The total score ranges from 0 to 100. Higher scores indicate greater fear avoidance.
Baseline
Numeric Pain Rating Scale
Lasso di tempo: Baseline
The Numeric Pain Rating Scale is used to assess self-reported pain intensity. Participants rate their pain intensity on an 11-point scale ranging from 0 (no pain) to 10 (worst imaginable pain). Pain intensity will be assessed at rest and during activity. Higher scores indicate greater pain intensity.
Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Akdeniz University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 maggio 2025

Completamento primario (Effettivo)

30 maggio 2026

Completamento dello studio (Effettivo)

5 giugno 2026

Date di iscrizione allo studio

Primo inviato

23 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

23 giugno 2026

Primo Inserito (Effettivo)

29 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • TBAEK-613/03.07.2025

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared because the study data will be collected from human participants and may include potentially identifiable demographic and clinical information. Data will be used only by the research team for the purposes of this methodological validation study. Aggregate results will be reported in scientific publications without identifying any participant.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Dolore spinale cronico

Prove cliniche su Questionnaire-based assessment

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in India

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi